Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
Corrado E., Saladino A., Morgante G., Mignano A., Nugara C., Novo G., et al. (2020). Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report. CLINICAL CASE REPORTS, 8(8), 1349-1352.
Data di pubblicazione: | 2020 |
Titolo: | Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report |
Autori: | |
Citazione: | Corrado E., Saladino A., Morgante G., Mignano A., Nugara C., Novo G., et al. (2020). Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report. CLINICAL CASE REPORTS, 8(8), 1349-1352. |
Rivista: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1002/ccr3.2655 |
Abstract: | Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan. |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
ccr3.2655 (1).pdf | N/A | Open Access Visualizza/Apri |